BioPharma Business Reports

Winning Product Launch Strategies: Maximizing sales from new pharmaceutical products

With pharmaceutical R&D continuing to suffer from declining productivity levels and stagnant returns on investment, effective, flexible and commercially successful new product launches have become more important than ever. How pharma companies drive product uptake and the effectiveness of their competitive positioning during the launch phase increasingly define pharmaceutical market success.

• Gain access to in-depth case studies of key launch strategies, enabling you to learn valuable lessons from industry leaders and implement these into your current processes.
• Analyze optimal launch timing and identify best practice examples for maximising your patent exclusivity period and successful early product launch strategies.
• Evaluate winning launch partnerships, analyze global licensing trends and implement strategies for future success.
• Identify key products, therapy areas and companies currently driving new product launch growth, including detailed analysis of 163 new product launches in the US and Europe for leading drugs.
• Identify key differences between US and EU approaches and implement current best practices for a successful product launch.

Indication Expansion: Opportunities for successful lifecycle management

Due to shrinking pipelines and rising financial pressures on pharmaceutical companies, indication expansion is an increasingly attractive strategy to expand patient potential and extend market exclusivity. Indication Expansion is a new report that provides in-depth case studies analyzing successful recent indication expansions and emerging trends. This report will enable you to avoid potential pitfalls whilst gaining a comprehensive review of how to delay generic competition and boost revenue growth.

• Understand the factors driving growth of indication expansion, and take advantage of future market trends.
• Develop indication expansion strategies by implementing best practice processes outlined in each case study.
• Identify emerging expansion trends including repositioning and indication removal.
• Gain access to analysis of the future of pediatric exclusivity and ensure your product pipeline is aligned with future market opportunity.
• Assess which companies are implementing successful indication expansion strategies and which therapy areas are the most popular

eHealth Solutions for Pharma: Strategies for salesforces, marketing, patient compliance and clinical trials

This new report provides an overview of the changing pharma market place, providing solutions on effective three way communication between pharmaceutical companies, patients and physicians. Use this report to identify ways to increase productivity and improve communications between your company, physicians and patients, and implement eHealth strategies to ensure your products achieve commercial success.

• Understand key challenges pharmaceutical sales and marketing teams are facing, and how eHealth technologies and best practice use of those technologies can offer significant improvement in productivity.
• Gain access to more physicians, using strategies outlined in this report including eDetailing, eSampling and websites, maximizing exposure of your products and strengthening communications with physicians
• Identify how eCompliance solutions can be implemented to improve the clinical trials process, enabling you to recruit physicians and promote patient compliance.
• Analyze the role of blogging and the fundamental impact it is having on the management of communications between pharma companies and patients.
• Evaluate eHealth strategies and gain best practice advice on the use of each of these technologies so that you can effectively implement these into your sales and marketing process.

Next Generation Protein Engineering and Drug Design: Strategies to boost efficacy and improve drug delivery

The success of protein and peptide therapeutics is revolutionizing the biotech and pharmaceutical market, spurring the creation of next-generation products with reduced immunogenicity, improved safety and greater effectiveness. Next Generation Protein Engineering and Drug Design provides a detailed insight into the current market for engineered proteins and peptides, and explores the key factors of commercial success for the development of next generation products. This report also provides in-depth analysis of patenting trends and market forecasts to 2011, enabling you to exploit innovative protein engineering technology in your drug discovery process.

Innovations in Cancer: Novel therapeutics, new diagnostics and future R&D strategies

A detailed insight into the evolution of the cancer market, the drivers and resistors of innovation and in-depth analysis of advances in both cancer therapeutics and diagnostics to provide a complete picture of how the cancer market will develop over the next five years. It also identifies key alliance and partnering opportunities highlighting companies with specialised capabilities in the discovery and the characterization of next-generation drug targets.

• Gain a detailed insight into the evolution of the cancer market, the drivers and resistors of innovation and how this will influence the development of future strategies.
• Identify the greatest areas of unmet medical need in the cancer field and how this continues to drive innovation, enabling you to anticipate future trends in the market.
• Assess your organisation's position in the market-place, identify competitive innovations and understand how companies are developing better drugs and diagnostics which will displace today's technologies.
• Discover the products that are being developed by the leading companies in the cancer market across the 'top four' cancers including breast, colorectal, lung and prostate.
• Understand how the use of oncogenomics will allow for better targeting of cancer, creating opportunities for the development of newer more effective products.

Innovations in CNS: Novel therapeutics and future R&D strategies

Novel therapeutics and future R&D strategies assesses novel treatments in development for major CNS disorders, comparing them with existing medications in terms of unmet need and forecasting their success in the commercial market. This report will enable you to understand the research tactics of your competitors and develop winning strategies for future growth in the lucrative CNS market. The report provides a survey of the pipelines of all of the major players in the CNS area. Detailed company profiles featured in the report include: AstraZeneca, GlaxoSmithKline, Merck & Co, Pfizer, and Sanofi-Aventis.

• Analyze patient potential, economic burden and key unmet needs in 10 major CNS disorders across the US, EU and Japan, including schizophrenia, depression and Alzheimer's disease.
• Understand how key preclinical and clinical trials are impactingCNS drug development, enabling you to assess new innovations andanticipate future trends in the market.
• Assess your organization's position in the market-place, and develop innovative future strategies to ensure you are positioned for success.
• Discover novel treatment strategies for all major therapeutic areas in psychiatry and neurology.
• Gain access to the CNS pipelines of leading companies including Sanofi-Aventis, Pfizer and AstraZeneca to understand their differing portfolio management strategies.

Biopartnering Strategies: Maximizing returns from biotechnology deal-making

Over the past 30 years the biotechnology industry has evolved rapidly, resulting in changes to biopartnering dynamics. Out-licensors now command greater power and leverage over the licensing of their technologies, changing the approach of out-licensing at various stages of the lifecycle and highlighting the need for biotechnology companies to adapt existing strategies to optimize this process. 'Biopartnering Strategies' is a unique report from the Drug Discovery series that provides an essential guide to the biopartnering process, for both in-licensing and out-licensing companies. Detailed case studies of biopartnering strategies at different phases of lifecycle development and in-depth analysis of deal trends will ensure that you can identify best practice alliance and licensing strategies and formulate successful deals.

Use this report to implement the optimal biopartnering strategy for your company's needs as it progresses through the 'pioneer', 'growth' and 'consolidation' stages of the lifecycle and ensure you recognize opportunities for growth in this high profit market.

Winning R&D Productivity Strategies: Exploiting innovation, licensing and outsourcing opportunities

Our new report; Winning R&D Productivity Strategies provides in-depth analysis of current issues affecting R&D, with assessment of challenges to productivity including, rising costs of drug development, attrition rates and clinical development times. This report analyzes solutions already being implemented to boost productivity and how these are evolving. Use this report to identify key areas of growth, effective strategies and innovative technologies to improve lead generation, attrition rates and return on investment from your portfolio.

• Identify strategies implemented by the biopharma industry to decrease R&D costs and increase productivity, and assess key trends and novel approaches to outsourcing and resource management which enable company re-structure and maximization of in-house resources.
• Assess key technology providers and establish which technologies should be implemented at various stages of the R&D process, enabling you to enhance productivity levels and gain a competitive edge.
• Benchmark your performance monitoring process, enabling you to choose the most appropriate markers to measure your own company productivity and assess your position within the industry.
• Develop innovative future strategies by utilizing the report's analysis of successful project and portfolio, licensing and partnership and resource management strategies by companies including Wyeth, GlaxoSmithKline and AstraZeneca.
• Anticipate future trends in the market, by using the report's predictions for areas of growth and gain insights into the outlook for innovative technologies in the R&D process.

The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities

The report evaluates current specialty pharma models, financial performance, core strategies and the future outlook of specialty pharma companies. This report also examines key specialty markets, providing valuable insights into market dynamics while profiling trends influencing market opportunities in therapeutic indications. Discover how leaders in the specialty pharma market are achieving high growth, benchmark your strategies against those of the industry 's leaders and identify profitable partnering opportunities with the help of this new report

Pharmaceutical Strategic Alliances: Maximizing returns from collaborative development and commercialization

Pharmaceutical Strategic Alliances provides in-depth case studies focusing on deal outcomes, and highlights key success factors in agreeing and executing strategic alliances. Use this report to understand the complexities of the various types of strategic alliances, analyze the key issues and critical success factors behind building and managing effective alliances and ensure you negotiate the best deal terms for your company.

Pharmaceutical Growth Opportunities in the EU Accession States: Healthcare reform, market dynamics and key players

A new report which provides in-depth insights into the competitive dynamics of the EU accession states. It identifies the key drivers and resistors of growth to enable you to understand the most important factors behind success in each country market. Use this latest report to determine key product opportunities, identify potential alliance partners and plan a successful and sustainable long term growth strategy to secure your leading position in the next five years.

Pharmaceutical Outsourcing Strategies: Market expansion, offshoring and strategic management in the CRO and CMO marketplace

A new report which provides a comprehensive and up to date review of contract research and manufacturing, in addition to key strategies for pharmaceutical companies to optimize their relationships with contractors. Emerging trends are evaluated and offshore outsourcing opportunities are analyzed in the rapidly growing markets of Eastern Europe, China and India. Use this report 's best practice case studies and unique examination of future outsourcing trends -including cutting edge technologies and novel contract alliances to ensure that you implement the optimal strategies for your company's needs.

Lifecycle Management Strategies: Maximizing ROI through indication expansion, reformulation and Rx-to-OTC switching

When a branded product loses patent protection, bioequivalent generic versions of the original compound can be launched by competitors, invariably at a lower price; this leads to strong competition for the branded product, which then experiences declining sales and market share. To maximize product sales and minimize the impact of generic competition, drug developers may utilize a variety of options including indication expansion, reformulation, second generation launch, Rx-to-OTC switch, own generic launch and divestiture. This report examines the circumstances under which each strategy can provide benefits, when each strategy is limited, and cases when the strategy was used successfully and unsuccessfully.